Geneva, Switzerland
Geneva, Switzerland

The Global Fund for Women is the a non-profit foundation funding women's human rights initiatives. It was founded in 1987 by New Zealander Anne Firth Murray, and co-founded by Frances Kissling and Laura Lederer to fund women's initiatives around the world. It is headquartered in San Francisco, California. Wikipedia.


Time filter

Source Type

News Article | February 27, 2017
Site: www.sciencemag.org

Leaks. Concerns about alienating President Donald Trump. Allegations about conflicts of interest. All of those reasons factored in to a surprise decision today by the board of the Global Fund to Fight AIDS, Tuberculosis and Malaria to restart its search for a new executive director. “Due to issues encountered in the recruitment process, the Board felt they were unable to bring the process to conclusion,” reads a statement issued by the Global Fund, which is based in Geneva, Switzerland. Since its launch in 2002, the Global Fund has given mainly poor countries more than $30 billion to fight public health threats. Donors to the fund include governments, foundations, and private industry, with the United States contributing about one-third of the total. Mark Dybul, the current head of the Global Fund, plans to step down at the end of May, and the group was expected today to select his successor from three candidates identified during a search this winter. Global Fund officials have asked its board members not to publicly discuss details of today’s decision to relaunch the search. The Global Fund’s spokesperson did not respond to an email. published a story today about the flap, and Insider has spoken with several people close to the proceedings. They say the trouble first surfaced when a Global Fund committee overseeing the nominations for the job wrote a report that ranked the top three candidates. obtained a copy of the report, submitted to the Board 13 February, and ran a story 2 days later that said one candidate, former Nigerian Minister of State for Health Muhammad Ali Pate, “has used Twitter posts to call Mr. Trump a fascist, saying he has much in common with ISIS for his anti-Muslim stance.” The story also said that “American officials may look askance” at a second candidate, Subhanu Saxena, who formerly headed the generic drug company Cipla, which has sold large volumes of drugs to the Global Fund. The third candidate was Helen Clark, head of the United Nations Development Program and previously a prime minister of New Zealand. According to the , Clark’s background raised concerns because the Trump administration “has expressed hostility toward United Nations programs.” According to one insider, the Board’s report on the candidates leaked to Clark early. She removed herself from the running, sending a statement to the Board that said she had concerns with the process. In an email, Pate stated that he has no plans to reapply for the job, noting that he was told the process was merit based and that he was the first-ranked candidate in the report. “The Global Fund Board's decision is unfair and unjustified,” Pate wrote. He charges that during the vetting process, “several efforts were made to question my candidacy on the basis that I was a Muslim, or that I am of Nigerian origin,” which he complained “smacks heavily of racism and Islamophobia that is now finding its roots in a respectable Global Health partnership of the Global Fund.” He wrote that it is “sad to see the Global Fund Board lacking the courage to stand up against discrimination.” Contrary to what the reported, Pate did not call Trump a fascist or suggest he had much in common with the Islamic State group. The story did later explain that Pate was forwarding Tweets from others that made these claims, one of which was a article and the other a headline from magazine. People familiar with the board’s deliberation today told Insider that there was little hope of reaching consensus about the two remaining candidates, and the participants generally agreed that the search process, conducted over the past 3 months—which included the holiday in December 2016—had been rushed. “And there were real concerns that because of the leaks, the process wasn’t fair,” says one. “The Global Fund is a well-functioning machine. This is one of the major global health entities in the world, and it has a vision and a strategy but needs a leader to inspire confidence, especially to the donors.”


Luers A.,The Global Fund
Climatic Change | Year: 2013

The US climate movement has failed to create the political support needed to pass significant climate policy. It is time to reassess climate advocacy. To develop a strategy for philanthropy to strengthen climate engagement, I interviewed over 40 climate advocates,more than a dozen representatives from the foundation community, and a dozen academics. My assessment led me to conclude that climate advocates have focused too narrowly on specific policy goals and insufficiently on influencing the larger political landscape. I suggest four ways to improve climate advocacy: 1) Increase focus on medium and longer-term goals; 2) Start with people and not carbon; 3) Focus more on values and less on science; and 4) Evaluate what works and share what we learn. To accomplish these strategies, social scientists and advocates must work together to build a culture of learning. Meanwhile, philanthropy must empower experimentation and incentivize knowledge sharing. © 2013 The Author(s).


Bridge J.,The Global Fund
International Journal of Drug Policy | Year: 2010

Multiple factors are implicated in the diffusion of injecting drug use (IDU), including individual and demographic characteristics, drug markets, economics, social networks and political and cultural environments. However, studies show that individual transitions away from injecting are possible, and that a recent diffusion of non-injecting routes of administration (NIROA) has occurred in several countries. Injecting is more risk-laden than other routes of drug administration, yet relatively little attention has been paid to reducing or preventing injecting drug use by promoting NIROA. This commentary reviews the case for, and examples of, 'route transition interventions' which seek to do this. These include: prescribing oral substitutes; providing non-injecting equipment; providing safer smoking facilities; and training individuals to prevent transitions to injecting, promote NIROA, or prevent the initiation of new injectors. These initiatives have the potential-as yet largely unrealised-to offer public health gains and empower people to control and manage their drug use. Further research is needed to secure commitments at all levels to support this approach. © 2010 Elsevier B.V. All rights reserved.


Patent
The Global Fund | Date: 2011-09-28

The invention relates to a solar tracking device for panels. The device includes a modular structure in which each module is formed by a plurality of pairs of coplanar panels (1) which are fixed to the ends of respective shafts (2) arranged at right angles to a longitudinal pivoting shaft (4) mounted on suitable supports secured to the ground. The pivoting shafts (4) of the modules (8) rotate simultaneously, each including a first radial arm (9) connected to a first common connecting rod (10). In turn, the coupling shafts (2) of each pair of panels (1) of a single module rotate simultaneously, each including respective second parallel radial arms (16), the free ends of which are hingeably connected to a second common connecting rod (15). One of the pivoting shafts (4) is rotated by means of a first linear actuator (11) which is secured to the ground and to a mounting box (13) for a radial lever (12) thereof. The solar tracking device is completed by means of a second actuator (20) which connects the mounting box (13) to one of the second radial arms (16).


News Article | March 1, 2017
Site: globenewswire.com

BETHLEHEM, Pa., March 01, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that its OraQuick® HIV Self-Test has been designated as eligible for procurement by purchasing entities entitled to access Global Fund and/or UNITAID resources. The OraQuick® HIV Self-Test has been classified by the Global Fund’s Expert Review Panel for Diagnostics as CATEGORY-2. The classification facilitates product procurement for 12 months with Global Fund and/or UNITAID resources. During this period, OraSure is expected to pursue and obtain WHO (World Health Organization) pre-qualification of the product or approval from another stringent regulatory agency. “We are pleased to have received the endorsement of the Global Fund’s Expert Panel,” said Douglas A. Michels, President and CEO of OraSure Technologies. “The classification enables government organizations implementing HIV self-test pilots and programs to access funding for the OraQuick® HIV Self-Test.  We expect the OraQuick® HIV Self-Test to be a valuable tool in reducing HIV infection rates globally.  The Global Fund’s action allows for the procurement of our test while we pursue WHO prequalification.” About the Global Fund and UNITAID The Global Fund is a partnership between governments, civil society, the private sector and people affected by diseases. The partnership organization is designed to finance programs aimed at accelerating the end of HIV/AIDS, tuberculosis and malaria as epidemics. For more information, please visit http://www.theglobalfund.org. UNITAID is engaged in finding new ways to prevent, treat and diagnose HIV/AIDS, tuberculosis and malaria. UNITAID identifies promising health solutions and invests in them to establish their viability in support of widespread adoption and impact. For more information, please visit http://www.unitaid.com. OraSure Technologies is a leader in the development, manufacture and distribution of point of care diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. Its first-to-market, innovative products include rapid tests for the detection of antibodies to HIV and HCV on the OraQuick® platform, oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications, and oral fluid laboratory tests for detecting various drugs of abuse. OraSure's portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians' offices, commercial and industrial entities and consumers. The Company's products enable healthcare providers to deliver critical information to patients, empowering them to make decisions to improve and protect their health. For more information on OraSure Technologies, please visit www.orasure.com.


Other HFM Awards this year include Best Administrator -- Small and Start-Up Firms in Europe and Best Administrator -- over $20bn Fund of Hedge Funds in Asia NEW YORK, NY--(Marketwired - Oct 24, 2016) - Custom House Global Fund Services, a leading independent hedge fund administration specialist, is pleased to announce that it has been honored by HFM Week as "Best Administrator - Under $30bn" in the annual US Hedge Fund Services Awards. Custom House was also nominated in three other categories for "Best Administrator" under $30bn single manager, under $30bn overall, and under $30bn for small and start-up firms. The awards, presented in New York on October 20, recognize and reward those hedge fund service providers that have demonstrated exceptional customer service and innovative product development over the past 12 months. John Lumley, Head of Business Development, Americas collected the award for Custom House. "Custom House has been very fortunate in hiring experienced professionals in the fund administration space that understand the needs of our clients," said Mark Hedderman, CEO, Custom House Global Fund Services. "Our exceptional client service has always been a key differentiator for Custom House and we are pleased to have received this recognition at this year's HFM Awards." "As Custom House has built its knowledge and prioritized client objectives for over 25 years, we see a great deal of opportunity for growth in North America to expand our business and offer best in class client service to this region," said Mr. Lumley. About Custom House Global Fund Services Custom House Global Fund Services is a leading independent hedge fund administration specialist ideally located to deliver services in Europe, Asia and the Americas. We partner with established hedge fund managers, start up managers, family offices and institutional managers, with a combination of experience, global presence and technology. Founded in 1989, Custom House grew with the alternative investment industry providing superior fund administration and investor services and today provides one of the most advanced service offerings available to fund managers. With over $20bn in AUA, Custom House provides fund administration services to more than 200 managers and 500 investment funds. The firm has offices in Chicago, Dublin, Geneva, Guernsey, Hong Kong, London, Malta, New York, Rotterdam, Shanghai, Shenzhen, Singapore, Sofia and Sydney. For more information, visit www.customhousegroup.com.


News Article | December 5, 2016
Site: www.prweb.com

Today, the United Nations Foundation’s Nothing But Nets campaign announced actress Nia Long and San Antonio Spur’s assistant coach Ime Udoka as new champions in the fight against malaria. In their first activity as Nothing But Nets champions, Long and Udoka are asking fans and family to help protect children and refugees from the disease by donating to the campaign. You can make a difference and save a life by donating $10 to purchase a net for a child and family in need. "Ime and I wanted to find an organization that spoke to us on a personal level; we both have family members who have been affected by malaria and we are dedicated to giving back to those in need,” Long said. “It is inconceivable that children are still dying from a disease which is completely preventable and treatable. We are proud to partner with the Nothing But Nets campaign to help raise awareness. A simple bed net can make all the difference for a child and family to prevent the spread of this deadly disease.” Every two minutes, a child dies from malaria. Nothing But Nets works closely with its UN partners across sub-Saharan Africa, to ensure vulnerable populations, including children, refugees, and families displaced by conflict, are protected from the disease. “We are thrilled to welcome Nia and Ime into the ranks of Nothing But Nets champions working across the country and around the world to raise awareness, funds, and voices to protect families from malaria,” said Margaret Reilly McDonnell, Director of Nothing But Nets. “We’re committed to working towards the day when no child dies from a mosquito bite.” Today, there are more than 65 million refugees and families displaced by violence around the world – and 60 percent of them live in areas where malaria is transmitted. Malaria is a major threat to refugees – it is a leading cause of illness and death in many African countries, including those where Nothing But Nets and its UN partners work. Last year, the campaign launched The Million Nets Pledge to protect refugee families from malaria with one million nets by 2016. This ambitious two-year goal aims to raise $10 million to protect vulnerable people fleeing violence, particularly in Central Africa. Now in its tenth year, the Nothing But Nets campaign boasts hundreds of thousands of supporters – from students to athletes to entertainers – who all help to protect families from the threat of malaria. Fans can join Long and Udoka in saving lives with Nothing But Nets by visiting NothingButNets.net/NiaLong. About Nothing But Nets Now in its tenth year, Nothing But Nets is a global campaign to save lives by preventing malaria, a disease which claims the life of a child every two minutes. Inspired by sports columnist Rick Reilly, hundreds of thousands of people have joined the campaign that was created by the United Nations Foundation in 2006. Nothing But Nets has raised $60 million to help deliver nearly ten million bed nets to families in need, along with other crucial malaria interventions. In addition to raising funds for its UN partners, Nothing But Nets raises awareness and voices to advocate for critical malaria funding for the U.S. President’s Malaria Initiative and The Global Fund to Fight AIDS, Tuberculosis and Malaria. It only costs $10 to help save lives from this deadly disease. Visit http://www.NothingButNets.net to defeat malaria. About The United Nations Foundation The United Nations Foundation builds public-private partnerships to address the world’s most pressing problems, and broadens support for the United Nations through advocacy and public outreach. Through innovative campaigns and initiatives, the Foundation connects people, ideas, and resources to help the UN solve global problems. The Foundation was created in 1998 as a U.S. public charity by entrepreneur and philanthropist Ted Turner and now is supported by philanthropic, corporate, government, and individual donors. Learn more at: http://www.unfoundation.org.


News Article | November 17, 2016
Site: www.prweb.com

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced the appointment of Ms. Shannon Trilli in the newly created role of Director of Corporate Responsibility. In her post, Ms. Trilli will be responsible for implementing Catalent’s global corporate responsibility strategy. She will strengthen Catalent’s efforts in this area, which will continue to be led by its Corporate Responsibility Council, composed of senior Catalent leaders from multiple functions. Ms. Trilli will coordinate and organize Catalent’s existing initiatives in sustainability and maximizing social impact, and its employee-driven community programs. She will also lead Catalent’s activities in establishing additional programs, including the matching of gifts and strategic volunteer initiatives, and the expansion of the organization’s philanthropic and partnership portfolio. Before joining Catalent, she served as the Director of Corporate Responsibility at S&P Global, a leading provider of transparent and independent ratings, benchmarks, analytics and data to capital and commodity markets worldwide. Prior to S&P Global, Ms. Trilli acted as the Director of Global Health for the United Methodist Committee on Relief (UMCOR). There, she designed, scaled and led UMCOR's Signature Health Program to provide funding and technical support to community based health organizations. She also led its $75 million "Imagine No Malaria" program in sub-Saharan Africa, with partners such as the U.N. Foundation and The Global Fund. Ms. Trilli has also served as a micro-enterprise development Peace Corps volunteer in Bolivia, and early in her career, was the manager of Global Employee Programs for the Contributions and Community Relations unit of The McGraw-Hill Companies. "In addition to more deeply engaging our communities and demonstrating Catalent's commitment to and improving health and the environment, Shannon’s appointment and implementation of the corporate responsibility strategy will help us more meaningfully connect to employees, customers, and stakeholders,” commented Alessandro Maselli, Catalent’s Senior Vice President of Global Operations. He added, “In her new role, she will help us effectively communicate how Catalent’s capabilities and values result in positive social and business impacts, both in our local communities and across the globe." Ms. Trilli earned a bachelor's in government from the University of Texas in Austin, and a master's degree in public administration from New York University. About Catalent Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 9,500 people, including over 1,400 scientists, more than 30 facilities across five continents, and in fiscal 2016 generated $1.85 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com


News Article | February 28, 2017
Site: www.nytimes.com

The Global Fund to Fight AIDS, Tuberculosis and Malaria will start looking again for an executive director after controversy over its first set of candidates.


NEW YORK, NY / ACCESSWIRE / December 7, 2016 / On December 1, 2016, Champion Pain Care Corporation (PINK SHEETS: CPAI) closed a Senior Secured Credit Facility (the Credit Facility) with TCA Global Credit Master Fund, LP (TCA) for a maximum $13 million senior secured line of credit, of which the initial line of credit is $6,500,000 is made available to the Company to fund acquisitions of pain management clinics and provide working capital. The terms of the Credit Facility are summarized in the Form 8-K and the accompanying exhibits filed by the Company on EDGAR on December 5, 2016. On the date of closing, $3,103,775 of the Credit Facility was advanced to close the acquisition of the assets of two pain management clinics in St. Augustine and Palatka, Florida, and to provide working capital. The Company intends to use the remaining amount, after fees, to fund additional acquisitions and provide more working capital. The Company, at the sole discretion of TCA, may request an increase in the line of credit at agreed upon time periods and agreed upon amounts. The sum of the Initial Line of Credit and the subsequent line increases, if any, (the Then Current Line Size) shall not exceed the maximum line of credit. Each subsequent line increase will require the Company to execute and deliver a new or revised revolving note to the Investor and be responsible for any fees and expenses associated with the line increase. Champion Pain Care Corporation (PINK SHEETS :CPAI, the Company) is a medical services holding company that is focused on creating a nation-wide network of clinics specializing in providing pain resolution treatments. Chronic pain alone affects 100 Million Americans and is a growing market as the population ages. Across the US, there are approximately 2,500 independent private pain management clinics operated by nearly 4,000 certified pain management specialists. It is the goal of the Company to acquire a number of those clinics, build a pain resolution network and create a national brand that pain patients will turn to for effective, economical and enduring pain treatments. To accomplish this, the Company plans to provide centralized management and administration, improve infrastructure, achieve economies of scale, implement standard operating procedures and best practices and engage in marketing directly to consumers. TCA Global Master Fund, (TCA), is a short duration, absolute return fund specializing in senior secured lending and advisory services to small, mainly listed companies predominantly in the United States of America, Canada, Western Europe and Australia. TCA's specialist business fills the underserved small-cap lending gap that exists in these leading markets. The TCA team has an unparalleled level of domestic and cross-border expertise, long-standing relationships and a history of comprehensive funding innovations. This reflects in its history of successful, completed transaction and high level of repeat business. Additional information may be found at www.tcaglobalfund.com. This press release may contain statements which constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the intent, belief or current expectations of the Company, its directors, or its officers with respect to the future operating performance of the Company. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties (for example, the risk that the acquisition of additional clinics are not consummated), and that actual results may differ materially from those in the forward-looking statements as a result of various factors. The Company's periodic filings with the Securities and Exchange Commission available at www.sec.gov should be viewed for a complete understanding of risk and uncertainty. Any forward-looking statements in this release speak only as of the date on which it is made. The Company assumes no obligation to update or revise any forward-looking statements. NEW YORK, NY / ACCESSWIRE / December 7, 2016 / On December 1, 2016, Champion Pain Care Corporation (PINK SHEETS: CPAI) closed a Senior Secured Credit Facility (the Credit Facility) with TCA Global Credit Master Fund, LP (TCA) for a maximum $13 million senior secured line of credit, of which the initial line of credit is $6,500,000 is made available to the Company to fund acquisitions of pain management clinics and provide working capital. The terms of the Credit Facility are summarized in the Form 8-K and the accompanying exhibits filed by the Company on EDGAR on December 5, 2016. On the date of closing, $3,103,775 of the Credit Facility was advanced to close the acquisition of the assets of two pain management clinics in St. Augustine and Palatka, Florida, and to provide working capital. The Company intends to use the remaining amount, after fees, to fund additional acquisitions and provide more working capital. The Company, at the sole discretion of TCA, may request an increase in the line of credit at agreed upon time periods and agreed upon amounts. The sum of the Initial Line of Credit and the subsequent line increases, if any, (the Then Current Line Size) shall not exceed the maximum line of credit. Each subsequent line increase will require the Company to execute and deliver a new or revised revolving note to the Investor and be responsible for any fees and expenses associated with the line increase. Champion Pain Care Corporation (PINK SHEETS :CPAI, the Company) is a medical services holding company that is focused on creating a nation-wide network of clinics specializing in providing pain resolution treatments. Chronic pain alone affects 100 Million Americans and is a growing market as the population ages. Across the US, there are approximately 2,500 independent private pain management clinics operated by nearly 4,000 certified pain management specialists. It is the goal of the Company to acquire a number of those clinics, build a pain resolution network and create a national brand that pain patients will turn to for effective, economical and enduring pain treatments. To accomplish this, the Company plans to provide centralized management and administration, improve infrastructure, achieve economies of scale, implement standard operating procedures and best practices and engage in marketing directly to consumers. TCA Global Master Fund, (TCA), is a short duration, absolute return fund specializing in senior secured lending and advisory services to small, mainly listed companies predominantly in the United States of America, Canada, Western Europe and Australia. TCA's specialist business fills the underserved small-cap lending gap that exists in these leading markets. The TCA team has an unparalleled level of domestic and cross-border expertise, long-standing relationships and a history of comprehensive funding innovations. This reflects in its history of successful, completed transaction and high level of repeat business. Additional information may be found at www.tcaglobalfund.com. This press release may contain statements which constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the intent, belief or current expectations of the Company, its directors, or its officers with respect to the future operating performance of the Company. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties (for example, the risk that the acquisition of additional clinics are not consummated), and that actual results may differ materially from those in the forward-looking statements as a result of various factors. The Company's periodic filings with the Securities and Exchange Commission available at www.sec.gov should be viewed for a complete understanding of risk and uncertainty. Any forward-looking statements in this release speak only as of the date on which it is made. The Company assumes no obligation to update or revise any forward-looking statements.

Loading The Global Fund collaborators
Loading The Global Fund collaborators